Why is IPH.PA stock falling pre-market?

IPH.PA stock is falling pre-market on 21 Mar 2026 mainly due to event risk ahead of the earnings announcement on 26 Mar 2026 and continued selling pressure from clinical uncertainty and negative earnings.

What are the nearest catalysts for IPH.PA stock?

The main catalysts are the earnings release on 26 Mar 2026 and any clinical updates for Monalizumab and Lacutamab. Positive trial news could reverse the current weakness in IPH.PA stock.

What is Meyka AI's price outlook for IPH.PA stock?

Meyka AI's forecast model projects a yearly price of **€1.39** (implied **+20.96%**) and a three-year price of **€0.50** (implied **-56.58%**). Forecasts are model-based projections and not guarantees.

How does IPH.PA stock compare to the Healthcare sector?

IPH.PA stock has negative EPS and a trailing PE of **-1.95**, versus a Healthcare sector average PE near **29.10**. The company shows higher leverage and weaker profitability than sector averages.

EU Stocks

Pre-market top loser: IPH.PA Innate Pharma €1.15 on 21 Mar 2026: earnings risk ahead

ByDanny Kontos March 21, 2026

IPH.PA stock opened pre-market at €1.15 on EURONEXT on 21 Mar 2026, trading as a top loser after extended declines that leave the share near its year low of €1.07. Today’s pre-market move follows heavy selling: volume at 145,608 shares versus an average of 160,904, and a one-day change of -0.35%. Investors face an upcoming earnings announcement on 26 Mar 2026, which is the most immediate catalyst for further downside or a short-term rebound.